Skip to main content
. Author manuscript; available in PMC: 2022 Jul 12.
Published in final edited form as: Annu Rev Pathol. 2022 Jan 24;17:387–402. doi: 10.1146/annurev-pathol-042320-034052

Figure 4.

Figure 4

Survival in chronic myeloid leukemia (CML) patients currently treated by the Max Access Solutions program, using imatinib as first-line therapy. At-risk patients from different areas are shown. Individual data points indicate deaths. Figure adapted with permission from Reference 16.